Volume 19 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(11): 1843-1845,1915
QI Ruo-bing, YANG Yong-xiu, JIANG Hui-quan, YIN Xiao-wen, CHEN Bin-hua, FEI Jian-hui, LEI Lan-ying, ZHANG Xue-ping. Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease[J]. Chinese Journal of General Practice, 2021, 19(11): 1843-1845,1915. doi: 10.16766/j.cnki.issn.1674-4152.002181
Citation: QI Ruo-bing, YANG Yong-xiu, JIANG Hui-quan, YIN Xiao-wen, CHEN Bin-hua, FEI Jian-hui, LEI Lan-ying, ZHANG Xue-ping. Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease[J]. Chinese Journal of General Practice, 2021, 19(11): 1843-1845,1915. doi: 10.16766/j.cnki.issn.1674-4152.002181
shu

Efficacy analysis of donepezil and memogen combined with risperidone in the treatment of mental behavioural symptoms of Alzheimer's disease

doi: 10.16766/j.cnki.issn.1674-4152.002181

  • Department of Gerontology, Hangzhou Seventh People's Hospital, Hangzhou, Zhejiang 310013, China

Funds:

 2018KY610

  • Received Date: 2020-12-11
    Abstract
  •   Objective  To analyse the efficacy and safety of donepezil and memantine combined with risperidone in the treatment of behavioural and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD).  Methods  A total of 150 patients with AD and BPSD who were admitted to Hangzhou Seventh People's Hospital from January 2017 to June 2019 were randomly divided into risperidone group (group A), risperidone+donepezil group (group B) and risperidone+donepezil+memogen group (group C) through a random number method, with 50 patients in each group. Before treatment, the positive and negative syndrome scale (PANSS), MOCA scale, blood sugar, triglyceride and cholesterol were recorded. Twelve weeks after treatment, the PANSS, MOCA scale, treatment emergent symptom scale (TESS), blood sugar, triglyceride, cholesterol test of the three groups were compared, with special attention to PANSS, MOCA scale, blood glucose, blood lipids and adverse reactions.  Results  After treatment, the MOCA and PANSS scores of group C patients were significantly improved compared with those of the other two groups. MOCA score of group A [(14.86±3.78) points], group B [(16.94±3.57) points] and group C [(19.10±3.73) points], the difference was statistically significant (F=9.858, P < 0.05). PANSS scores were (110.52±11.55) points in group A, (99.96±8.47) points in group B and (86.14±5.48) points in group C, and the difference was statistically significant (F=94.100, P < 0.05). The incidence of adverse reactions was lower in group C than that in the other two groups, and the results were statistically significant. After treatment, the improvement of blood glucose, blood lipid, TESS and risperidone dosage in group C was more obvious than that in groups A and B.  Conclusion  Risperidone+donepezil group and risperidone+donepezil+memantine groups have better cognitive function improvement after treatment of BPSD, less side effects, reduced dose of risperidone drug treatment and improved quality of life.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    万素馨, 方伟. 阿尔茨海默病的治疗药物作用机制研究进展[J]. 现代药物与临床, 2018, 33(12): 3406-3410. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZW201812070.htm
    [2]
    彭也, 朱天碧, 张钊, 等. 阿尔茨海默病的免疫调控研究进展[J]. 中国药理学通报, 2019, 35(4): 445-451. doi: 10.3969/j.issn.1001-1978.2019.04.001
    [3]
    杜荣蓉, 曲连悦, 孙珊珊, 等. 阿尔茨海默病的药物治疗研究现状[J]. 中国临床药理学杂志, 2019, 35(5): 489-492. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201905024.htm
    [4]
    周源源. 阿尔茨海默病的流行病学、发病危险因素、治疗及早期筛查研究进展[J]. 内科, 2019, 14(6): 690-692. https://www.cnki.com.cn/Article/CJFDTOTAL-NKYT201906019.htm
    [5]
    王晓珍, 王蓉. 阿尔茨海默病的药物治疗及研发进展[J]. 中国新药杂志, 2019, 28(24): 2960-2964. doi: 10.3969/j.issn.1003-3734.2019.24.007
    [6]
    程喆歆, 梁庆成, 吴云, 等. 阿尔茨海默病的发病机制及药物治疗的研究进展[J]. 现代生物医学进展, 2017, 17(10): 1981-1985. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201710049.htm
    [7]
    段玉梅, 文国强. 阿尔茨海默病危险因素及预防策略的研究进展[J]. 海南医学, 2020, 31(2): 224-227. doi: 10.3969/j.issn.1003-6350.2020.02.025
    [8]
    杨柳. 脑兴奋性突触后NMDA受体信号转导复合物[J]. 国外医学(生理、病理科学与临床分册), 2005, 2(3): 207-210. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB200503005.htm
    [9]
    王菁. 多奈哌齐联合尼莫地平治疗阿尔茨海默症临床效果[J]. 慢性病学杂志, 2020, 21(2): 177-179. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO202002007.htm
    [10]
    宋博雅. 阿尔兹海默症发病机制的研究进展[J]. 西安文理学院学报(自然科学版), 2020, 23(4): 77-79, 92. doi: 10.3969/j.issn.1008-5564.2020.04.016
    [11]
    COLOM-CADENA M, SPIRES-JONES T, ZETTERBERG H, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease[J]. Alzheimer's Res Ther, 2020, 12(1): 21. doi: 10.1186/s13195-020-00588-4
    [12]
    何志军, 陈杰瑞, 薛华, 等. 阿尔茨海默症与2型糖尿病的共病机制及硒与钒的作用[J]. 生命科学, 2020, 32(6): 597-605. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX202006011.htm
    [13]
    赵丽萍, 缪林清, 蒋鹭莲, 等. 针刺改善阿尔茨海默病氧化应激机制的研究现状与思考[J]. 世界科学技术-中医药现代化, 2020, 22(8): 2670-2678. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202008012.htm
    [14]
    胡建庆, 赵俊, 卢梦晗, 等. "通督启神"针法治疗阿尔茨海默病的理论探讨[J]. 世界科学技术-中医药现代化, 2020, 22(8): 2634-2640. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202008006.htm
    [15]
    邱聪龙, 张怡, 陈寿林, 等. 不同程度阿尔茨海默病患者血脂水平的研究[J]. 中华全科医学, 2020, 18(12): 2043-2046. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202012019.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (379) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return